SMRT antibody 
- Host / ClonalityMouse Monoclonal
- Clone Name1542
- ApplicationsIP, WB
- Species reactivityHuman
SMRT antibody  validated data
SMRT antibody 
|Full Name||nuclear receptor corepressor 2|
|Synonyms||600848, 9612, TNRC14, SMRT, TRAC1, SMRTE, TRAC-1, SMRTE-tau, NCOR2, CTG26, Q9Y618, SMRTEtau, TRAC 1, SMRTE tau|
|Product Description||Mouse monoclonal antibody to human SMRT|
|Background||SMRT-1542 recognizes the Silencing Mediator for Retinoid and Thyroid receptors (SMRT) gene product, a 168 kDa nuclear protein. Nuclear hormone receptors are transcription factors regulated by ligand binding. In the absence of ligand there is a physical interaction between the nuclear receptors that do not interact with Hsp90 and a family of corepressors which includes SMRT. SMRT helps target histone deacetylases and other components of a multiprotein repressor complex to the specific target promoter to silence gene transcription|
|Immunogen||A synthetic peptide from the human SMRT protein corresponding to amino acids 994-1005 (ASASDPHREKTQ) coupled to KLH.|
|Application Note||For IP: Use at an assay dependant concentration. For WB: Use at an assay dependant dilution. Predicted molecular weight: 274 kDa. Not tested in other applications. Optimal dilutions/concentrations should be determined by the researcher.|
|Predicted Target Size||168 (note)|
|Purification||Protein G Affinity Purified|
|Purification Note||From hybridoma tissue culture supernatant|
|Storage Buffer||Phosphate-buffered saline, pH 7.4, containing no preservatives |
|Storage Instruction||Keep as concentrated solution. Store at 4°C short term. For extended storage aliquot and store at -20°C or below. Avoid freeze-thaw cycles.|
for SMRT antibody 
Why is the observed Western Blot band size different from predicted size?
The predicted M.W. is based on protein sequence analysis; however, some factors might lead to an observed band size that is different from the predicted size. The reasons might include:
1.Post-translational modification (PTM):
a. Some post-translational modifications might lead to increased protein size, including
phosphorylation, acetylation, methylation, glycosylation, sumoylation, ubiquitination,
b. Some post-translational modifications might lead to decreased protein size including
phosphatidylethanolamine conjunction (e.g. LC3-II)
c. Some proteins may be cleaved to form an active or mature form; this process will
lead to a decreased protein size (e.g. Notch activation, Caspase activation, etc.)
d. Some websites provide useful PTM information
iv.CBS data sets http://www.cbs.dtu.dk/databases/
v.CBS prediction Servers http://www.cbs.dtu.dk/services/
2.mRNA splice variants (Isoforms):
Through alternative splicing, one gene can generate different proteins with different M.W. Regulation of alternative splicing depends upon cell type, conditions, etc.
Some proteins could form dimers or multimers, increasing the M.W. This phenomenon usually can be found in reducing gel condition; however, strong interactions may still be seen with higher molecular weight proteins even in denaturing gel.
The observed size could also potentially be influenced by the protein charge
Different species likely have different protein sequence and PTM, which can lead to a different protein M.W.
© 2013 GeneTex Inc. All rights reserved.